A new research ecosystem has been set up in Finland in which the country’s leading research organisations, together with the Finnish Red Cross Blood Service, Orion Pharma and nanotechnology SMEs, are joining forces to develop new types of nanobiotechnological solutions for the treatment and early diagnostics of severe progressive diseases.
A Review article summarizing the Potential of Levosimendan in the Management of ALS: Overview of a Working Hypothesis
The REFALS trial is studying the effects of oral levosimendan in patients with amyotrophic lateral sclerosis (ALS).
Helping patients is the greatest motivation for the research team at Orion. Even the smallest successes inspire the researcher to work harder.
"I’m inspired by our input in research and product development. For example, great opportunities may be presented by biologic drugs, which are being developed extensively around the world", says Christer Nordstedt.
"The tasks of a doctor in the pharmaceutical industry are versatile and educational", says Kristiina Kuismanen.